Fetal Fibronectin Testing
Pre-term birth is a significant health issue in Canada. In an effort to avoid unnecessary antepartum admissions or maternal transfers, many jurisdictions have adopted Fetal Fibronectin (ƒFN) testing for women with symptoms of pre-term labour. To assist health-care professionals and planners with the implementation and monitoring of a testing program, a Working Group with representatives from across Canada developed the following resources: a clinical guideline, a presentation, and a list of key indicators. These documents are provided as templates and can be adapted based on local circumstances.
| Clinical Guideline |  |
|
 |
 |
|
| Presentation |  |
|
 |
||
| List of Key Indicators |  |
|
|
|
|
RCP has worked in collaboration with regional hospitals across Nova Scotia to implement fetal fibronectin (fFN) testing to diagnose preterm labour. On December 4, 2006, Dr. Heather Scott, Obstetrical Co-Director of RCP, along with Rebecca Attenborough, Coordinator RCP, and Mike Mahaffa, Adeza Biomedical Representative gave the following presentation via telehealth on the implementation and use of fFN in Nova Scotia.
| Video presentation (December 2006, 43 minutes) |  |
|
 |
 |
|
Et, en français, nous avons la présentation de Lucie Morin, MD, FRCSC, professeure agrégée de clinique, dép. d'obstétrique-gynécologie, CHU Sainte-Justine.
| Présentation vidéo (2007, 53 minutes) |  |
|
|
|
|